

TEVA-SPONSORED VIRTUAL SATELLITE  
SYMPOSIUM AT THE 7<sup>TH</sup> CONGRESS OF  
THE EUROPEAN ACADEMY OF NEUROLOGY

# Current and future approaches to migraine prevention

20  
JUN

13:45–14:45 CEST  
JOIN ONLINE



teva

# Current and future approaches to migraine prevention



## WELCOME

Dear colleagues,

**With great pleasure, I invite you to join us at this Teva-sponsored satellite symposium, taking place during the virtual 7<sup>th</sup> Congress of the European Academy of Neurology (EAN).**

Efficacy and safety data from clinical trials of monoclonal antibodies targeting the CGRP pathway (anti-CGRP mAbs) have supported their adoption in practice; however, several questions remain surrounding treatment goals, long-term use and other clinical considerations.

During this virtual symposium, we will discuss preventive treatment outcomes beyond a reduction in migraine or headache days and provide an update on some of the latest long-term data relating to anti-CGRP mAbs, including patient dosing preferences. Looking to the future, we will also consider ongoing real-world studies and how emerging data from these may help to answer outstanding questions, such as starting and stopping rules and switching.

I hope you will join us for what promises to be an engaging and informative symposium.

**Zaza Katsarava, Chair**  
Christian Hospital Unna and  
University of Duisberg-Essen  
Essen, Germany



To register for the virtual EAN congress, please visit [www.ean.org/congress-2021/discover/register](http://www.ean.org/congress-2021/discover/register). The symposium will include the opportunity to ask questions to the faculty throughout the presentations.



## PROGRAMME



Welcome  
**Zaza Katsarava,**  
Germany (Chair)



Rethinking preventive treatment goals in the CGRP era  
**Hans-Christoph Diener,**  
Germany



Long-term use of anti-CGRP mAbs: what do we know?  
**Dagny Holle-Lee,**  
Germany



Looking to the future: what can we expect next from anti-CGRP mAbs?  
**Piero Barbanti,** Italy



Panel discussion and closing remarks  
**Facilitated by**  
**Zaza Katsarava**